Access Bio
10 products found

Access Bio products

Analyzers

AccessBio careSURE - A1c Cartridge

Method comparison. careSURE™ Analyzer 100 vs. a laboratory HPLC method (Tosoh G11) Using 48 venous blood samples.

AccessBio careSURE - Neonatal Care Analyzer

A neonatal solution, the S1 Analyzer is capable of quantifying total G6PD, Hemoglobin, and Bilirubin levels. Early diagnosis for newborns are crucial to ensure healthy development. The S1 Analyzer’s handheld format, with Bluetooth and wifi technology, affords patient-side accuracy and convenience.

Covid-19 Detection Kits

CareStart - COVID-19 Antigen for Rapid POC Test

The CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within the first five days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.

AccessBio CareStart - Antigen Home Test Kit

Self Test for SARS-CoV-2 Antigen Detection. The CareStart™ COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigens from SARS-CoV-2. Fast and easy to self-test at anywhere. Easy to interpret the results using mobile application. Qualitatively detect the SARS-CoV-2 nucleocapsid protein. Use for nasal swab specimen. Fast results only in 10 minutes. Identify individual’s current infection status to COVID-19.

CareStart - COVID-19 Detection Kits

The CareStart™ COVID-19 MDx RT-PCR is a real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory specimens (such as nasopharyngeal, oropharyngeal and nasal swabs, and nasopharyngeal wash/aspirate or nasal aspirate) and bronchoalveolar lavage from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests.